A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy (NCT07096843)

🧪 Interventions in This Study

• budoprutug (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Confirmed diagnosis of PMN with positive anti-PLA2R antibodies
2. CD19+ B cell count ≥40 cells/μL
3. UPCR ≥2.0 g/g
4. eGFR ≥35 mL/min/1.73 m²
5. Stable RAAS inhibitor therapy
6. Blood pressure \<150/90 mmHg at baseline
7. Adequate hematologic, hepatic, and renal function
8. Willing to use effective contraception (both sexes)
9. Other inclusion criteria may apply

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (43 Sites)

Showing the first 25 of 43 sites.

• Climb Bio Investigative Site #110 — Denver, Colorado
• Climb Bio Investigative Site #105 — Orlando, Florida
• Climb Bio Investigative Site #108 — Atlanta, Georgia
• Climb Bio Investigative Site #106 — Indianapolis, Indiana
• Climb Bio Investigative Site #111 — Boston, Massachusetts
• Climb Bio Investigative Site #101 — Clifton Park, New York
• Climb Bio Investigative Site #104 — Sherman, Texas
• Climb Bio Investigative Site# 602 — Buenos Aires,
• Climb Bio Investigative Site# 603 — Buenos Aires,
• Climb Bio Investigative Site #601 — CABA,
• Climb Bio Investigative Site #604 — CABA,
• Climb Bio Investigative Site #606 — Santa Fe,
• Climb Bio Investigative Site #502 — Belo Horizonte,
• Climb Bio Investigative Site #505 — Minas Gerais,
• Climb Bio Investigative Site #506 — Pernambuco,
• Climb Bio Investigative Site #501 — Porto Alegre,
• Climb Bio Investigative Site #503 — São Paulo,
• Climb Bio Investigative Site #504 — São Paulo,
• Climb Bio Investigative Site #701 — Temuco, Araucania
• Climb Bio Investigative Site #703 — Valdivia, Los Ríos Region
• Climb Bio Investigative Site #702 — Santiago, Santiago Metropolitan
• Climb Bio Investigative Site #403 — Beijing, Changping District
• Climb Bio Investigative Site #401 — Beijing, Cheng District
• Climb Bio Investigative Site #408 — Shenzhen, Guangdong
• Climb Bio Investigative Site #402 — Wuxi, Jiangsu

📞 Contact the Study Coordinator

Phone: (866) 857-2596

Email: clinicaltrials@climbbio.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Primary Membranous Nephropathy

• Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) — Montgomery, Alabama
• A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy — Granada Hills, California
• Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) — Loma Linda, California
• A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) — Huntsville, Alabama
• A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy — San Francisco, California

Explore by condition: All Primary Membranous Nephropathy clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.